HARMFUL AND PROTECTIVE ROLES OF NEUTROPHILS IN SEPSIS

Laszlo M. Hoesel, Thomas A. Neff, Simona B. Neff, +7

Shock

InflammationCytokineExperimental SepsisGranulocyteInnate Immune System +12

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Naresh Bumma, Joshua Richter, Sundar Jagannath, +29

Journal of Clinical Oncology

Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition

Matthew J. Pianko, Sean M. Devlin, Eric R. Littmann, +16

Blood Advances

Ability of Antioxidant Liposomes to Prevent Acute and Progressive Pulmonary Injury

Laszlo M. Hoesel, Michael A. Flierl, Andreas D. Niederbichler, +9

Antioxidants and Redox Signaling

Acute Lung InjuryInflammatory Lung DiseaseProgressive Pulmonary InjuryLung InflammationLipid Peroxidation +18

C5a-Blockade Improves Burn-Induced Cardiac Dysfunction

Laszlo M. Hoesel, Andreas D. Niederbichler, Julia Schaefer, +12

The Journal of Immunology

Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study

Hira Mian, Tanya M. Wildes, Ravi Vij, +3

Blood Cancer Journal

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets

Urvi A. Shah, Kylee Maclachlan, Andriy Derkach, +35

Clinical Cancer Research

Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay

Katie Thoren, Matthew J. Pianko, Youssef Maakaroun, +2

The Journal of Applied Laboratory Medicine

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma

Emily Hoylman, Anna Brown, Anthony J. Perissinotti, +5

Leukemia & lymphoma/Leukemia and lymphoma

ImmunologyPathologyImmunotherapyHematological MalignancyOptimal Sequence +14

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Sundar Jagannath, Joshua Richter, Madhav V. Dhodapkar, +26

Blood